• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sagimet Biosciences Inc. - Series A Common Stock (NQ: SGMT )

    5.150 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Sagimet Biosciences Inc. - Series A Common Stock

    < Previous 1 2 3 Next >
    Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024
    SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
    Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET 
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    What's Going On With Sagimet Biosciences Stock On Thursday?
    Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress. 
    Via Benzinga
    Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
    Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
    Via Benzinga
    Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
    Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH 
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024
    SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
    Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024 
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
    Via Benzinga
    Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
    Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
    Via The Motley Fool
    Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.